Structure Therapeutics (GPCR) said Monday patients who took a high dose of its GLP-1-targeted obesity treatment lost up to 15.3% more body weight than placebo recipients. Structure Therapeutics stock rose sharply in early trades. The results support plans to begin a Phase 3 study in mid-2026, Structure said in a news release. Chief Executive Raymond Stevens said patients who took…
